SNIBE(SZ:300832) Huachuang Securities·2025-12-02 10:13Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 78 yuan [2][8]. Core Insights - The company reported a revenue of 3.428 billion yuan for the first three quarters of 2025, reflecting a slight increase of 0.39% year-on-year, while the net profit attributable to the parent company decreased by 12.92% to 1.205 billion yuan [2]. - The overseas business is experiencing rapid growth, with a 21% year-on-year increase in revenue, particularly in the reagent business, which saw a 37% increase [8]. - The company is optimizing its installation structure, with 1,144 automated chemical luminescence instruments installed in the domestic market, 78% of which are large machines, indicating a significant improvement compared to the same period in 2024 [8]. Financial Performance Summary - For 2025, the company expects total revenue to reach 4.787 billion yuan, with a year-on-year growth rate of 5.6% [4]. - The net profit attributable to the parent company is projected to be 1.786 billion yuan, reflecting a slight decline of 2.3% [4]. - The earnings per share (EPS) for 2025 is estimated at 2.27 yuan, with a price-to-earnings (P/E) ratio of 26 [4]. Market Dynamics - The domestic market is facing challenges, with a 11% decline in main business revenue to 1.955 billion yuan due to factors like centralized procurement and unbundling of testing packages [8]. - The overseas market is less affected by policy uncertainties, and the gross margin for overseas operations has improved to 69.49%, surpassing domestic levels [8]. - The company is transitioning to higher-margin X-series products, which is expected to support long-term growth [8].